MENU
Advertisement
News | March 31, 2026Mar312026
EMBRACE to Study Medtronic’s Symplicity Spyral RDN System With Staged PCI
March 31, 2026—Medtronic announced it is supporting the investigator-initiated EMBRACE trial of the company’s Symplicity Spyral renal denervation (RDN).
News | March 11, 2026Mar112026
Verve’s United States Pilot Trial of Renal Pelvic Denervation Therapy Enrolls First Patient
March 11, 2026—Verve Medical, a developer of noninvasive renal pelvic denervation (RPD) technology, announced the treatment of the first patient in its randomized, double-blinded United States pilot clinical trial for the treatment of uncontrolled hypertension.
Medtronic Symplicity Spyral RDN Studied in Pooled Analyses from SPYRAL HTN Program
March 11, 2026—New analyses from the SPYRAL HTN clinical study program presented at CRT 2026 reported long-term outcomes with the Symplicity Spyral radiofrequency (RF) renal denervation (RDN) system (Medtronic), including a pooled 3-year efficacy analysis, a study of hypertensive urgencies, and the design of the SPYRAL CARE real-world study.
News | March 2, 2026Mar022026
Otsuka’s Paradise uRDN System Launched in Japan With National Health Insurance Coverage
March 2, 2026—Otsuka Medical Devices Co., Ltd. and Otsuka Pharmaceutical Co., Ltd., announced the commercial launch of the Paradise ultrasound renal denervation (uRDN) system.
News | February 19, 2026Feb192026
Medtronic Secures Japan Reimbursement for Spyral RDN
February 19, 2026—Medtronic plc announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted reimbursement approval for the Symplicity Spyral renal denervation (RDN) system (Medtronic) for the treatment of resistant hypertension.
News | January 30, 2026Jan302026
Gore Viatorr TIPS Endoprosthesis Expanded Diameter Range Gains CE Mark Approval
January 30, 2026—Gore & Associates announced European CE Mark approval of a 6- to 10-mm diameter range for the Gore Viatorr TIPS—transjugular intrahepatic portosystemic shunt—endoprosthesis with controlled expansion.
News | November 18, 2025Nov182025
Neurotronic’s Neuviant Multiorgan Denervation Studied to Treat Type 2 Diabetes and Hypertension
November 17, 2025—Neurotronic, Inc. announced the first clinical outcomes of the NECTAR III and NECTAR IV trials evaluating the company’s Neuviant multiorgan denervation (MDN) system in patients with both type 2 diabetes mellitus (T2DM) and hypertension (HTN).
News | October 29, 2025Oct292025
CMS Finalizes National Coverage Determination for Renal Denervation Systems
October 29, 2025—The Centers for Medicare & Medicaid Services (CMS) has released the final National Coverage Determination (NCD) on renal denervation (RDN).
News | October 27, 2025Oct272025
New Diameter Range Approved for Gore’s Viatorr TIPS Endoprosthesis With Controlled Expansion
October 27, 2025—Gore & Associates announced FDA approval of a 6- to 10-mm diameter range for the Viatorr TIPS—transjugular intrahepatic portosystemic shunt—endoprosthesis with controlled expansion.
News | October 26, 2025Oct262025
Long-Term SPYRAL HTN-ON MED Data Presented for Medtronic’s Symplicity Spyral RDN System
October 26, 2025—Medtronic announced that long-term results from its final report of the SPYRAL HTN-ON MED trial showed that patients treated with the company’s radiofrequency-based Symplicity Spyral renal denervation (RDN) procedure experienced significantly greater reductions in blood pressure compared to sham patients through 3 years.
News | September 12, 2025Sep122025
Pulnovo’s PADN System Receives Two IDE Approvals for Pulmonary Hypertension
September 12, 2025—Pulnovo Medical, a Shanghai, China-based developer of medical devices for pulmonary hypertension (PH) and heart failure, announced that its pulmonary artery denervation (PADN) catheter and generator received two investigational device exemption (IDE) approvals from the FDA.
News | September 2, 2025Sep022025
Medtronic’s Symplicity Spyral Renal Denervation System Approved in Japan
September 2, 2025—Medtronic announced that its Symplicity Spyral renal denervation (RDN) system has been approved by Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for the treatment of resistant hypertension.
News | August 25, 2025Aug252025
Otsuka Medical Devices Announces Japan Approval of Paradise uRDN System
August 25, 2025—Otsuka Medical Devices Co., Ltd. announced that the Paradise ultrasound renal denervation (uRDN) system has received manufacturing and marketing approval in Japan for the treatment of resistant hypertension.
News | July 7, 2025Jul072025
Medtronic’s SPYRAL GEMINI Multiorgan Denervation Study Begins Enrollment
July 7, 2025—Medtronic announced that the first patient has been treated in its SPYRAL GEMINI global pilot study, which will investigate the safety and potential efficacy of multiorgan denervation (MDN) in patients with uncontrolled hypertension (HTN).
News | June 11, 2025Jun112025
Medtronic’s GSR-DEFINE Study of Symplicity Spyral RDN System Enrolls First United States Patient
June 11, 2025—Medtronic announced the treatment of the first patient in the United States in the GSR-DEFINE clinical trial.
News | June 10, 2025Jun102025
ACC and BIDMC Smith Center Collaborate on Renal Denervation Registry
June 10, 2025—The American College of Cardiology (ACC) reported that the Richard A. and Susan F. Smith Center for Outcomes Research at Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts, and ACC are collaborating on a renal denervation (RDN) module that leverages the Smith Center’s RDN Registry and the ACC CathPCI Registry.
News | May 19, 2025May192025
Gradient’s Pulmonary Artery Denervation System Receives FDA Breakthrough Designation
May 19, 2025—Gradient Denervation Technologies, which is based in Paris, France, announced that the company’s pulmonary artery denervation (PADN) system has received FDA Breakthrough Device designation.
News | March 19, 2025Mar192025
Route 92’s Monopoint Venous Sinus System Studied to Treat Idiopathic Intracranial Hypertension
March 19, 2025—Route 92 Medical, Inc. announced the results of a multicenter study evaluating the utility of the company’s Monopoint venous sinus system in neurovascular interventional procedures to treat idiopathic intracranial hypertension.
News | March 3, 2025Mar032025
Boston Scientific to Acquire SoniVie
March 3, 2025—Boston Scientific Corporation announced it has entered into a definitive agreement to acquire SoniVie Ltd., a privately held medical device company that has developed the Tivus intravascular ultrasound system for denervation of renal nerves surrounding blood vessels to treat a variety of hypertensive disorders.
News | January 13, 2025Jan132025
CMS Initiates NCA on Renal Denervation for Uncontrolled Hypertension
January 13, 2025—Medtronic and Recor Medical, Inc. separately announced that the Centers for Medicare & Medicaid Services (CMS) is opening a national coverage analysis (NCA; CAG-00470N) on renal denervation (RDN) for uncontrolled hypertension.
Much Supply Confers Great Demand: Renal Denervation for Resistant Hypertension
A discussion of a challenging case of renal artery denervation for resistant hypertension.
By Brian Fulton, MD; Taisei Kobayashi, MD; and Jay Giri, MD, MPH
What’s Your Approach?
By Herb Aronow, MD, MPH, FACC, MSCAI, MSVM
How to Denervate With Current Renal Denervation Device Iterations
A step-by-step guide to renal denervation for the treatment of hypertension.
By Brian Fulton, MD; Jay Giri, MD, MPH; Debbie L. Cohen, MD; Herbert D. Aronow, MD, MPH; and Taisei Kobayashi, MD
Current Evidence for Catheter-Based Renal Denervation for Hypertension
A review of the evidence for a novel treatment for hypertension.
By Anna K. Krawisz, MD, and Eric A. Secemsky, MD, MSc, RPVI, FACC, FAHA, FSCAI, FSVM
Team Approaches to Hypertension Management: New Opportunities for Interventionalists
A multidisciplinary approach to hypertension is necessary to achieve optimal outcomes, with interventionalists increasingly involved with the reemergence of promising nonpharmacologic options such as renal denervation.
By Klevin Roger L. Reyes, MD; Gizem Bilgili, MD; and Florian Rader, MD, MSc
Sponsored by ROX Medical
Considering a New Approach to Treatment of Uncontrolled Hypertension With the ROX Coupler Device
A discussion with Dr. Krishna Rocha-Singh and Prof. Dr. Felix Mahfoud on what makes the ROX Coupler device different from other hypertension interventions, how to implant the device, clinical study results, and anticipated results from ongoing studies.
With Krishna Rocha-Singh, MD, and Felix Mahfoud, MD
May 2025
Leveling Up in Limb Preservation
Multifaceted approaches to delivering truly meaningful and better outcomes in CLTI.
View Issue
April 2025
What's Your Approach?
Highlights in decision-making across a variety of challenging case scenarios.
January 2023
Multidisciplinary Teamwork
How leading centers are leveraging diverse skill sets and opinions to improve patient outcomes and efficiency.
Identifying Opportunity in Challenge
By Barry T. Katzen, MD
Resistant Hypertension: Clinical Considerations and the Potential for Renal Denervation
By Vikas Kapil, MD, MRCP, PhD, and Melvin D. Lobo, MD, FRCP, PhD